Q4 2023 Presentation
1 March 2024
Today's presenters
Sverre Flatby | Einar Bonnevie |
Chief Executive Officer | Chief Financial Officer |
18 years with Omda | 15 years with Omda |
9.7% equity stake in Omda1) | 9.7% equity stake in Omda1) |
Note: 1) Through Equilibrium AS | 2 |
Vision:
Smarter ways to a safe and healthy world
Mission:
Providing proven, focused software for health and emergency professionals to know more and work smarter.
3
Specialised software ->long-term income predictability
Risk of customer churn
Primary
care
Community
care
Long-term
care
Omda's organic growth and M&A strategy secures long-term recurring revenues with low churn
Emergency Specialised
care care
Length of solution replacement projects
4
Software niches - business areas
Emergency | Woman & Child | Medication Management | ||
Managing every aspect of the | Safeguarding pregnancy, | Decision support, safe and | ||
emergency response value chain | childbirth and infancy | effective oncology treatments | ||
Connected Imaging | LIMS | Health Analytics |
Leading imaging solutions and | End-to-end blood, cell, and tissue |
secure information sharing | management |
Improving the quality of medical data from collection to analysis
5
Long-term recurring revenue with minimal churn….
1
Recurring Revenue
78%
4 Otherincome
2
License Sales
1 Sales
split FY 2023 4
2 | 3 | 2% | 3 | Professional |
Services |
18%
3%
Recurring revenue | Software revenue | Semi-recurring |
6
…from solid public healthcare customers
>20
years
>10
years
Note: 1) Churn of recurring revenue from lost contracts
Solid counterparties
+90% of revenue from public healthcare accounts
High stickiness
Predictable revenues for years, sometimes decades
High diversification
+600 contracts across
27 countries
- 2% churn1)
Mission-critical systems favours contract continuity
7
Performance Q4-2023 compared to Q4-2022
109 MNOK
Q4'23
vs 98 MNOK Q4'22
6,6%
COGS Q4´23
vs 10% Q4´22
11%
Income growth
Q4'23 vs Q4'22
60%
Salary cost Q4'23
vs 75% Q4'22
(% of total revenue)
12%
Annual
revenue
growth YoY
2023 vs
2022
283
Employees
Q4'23
vs 315 Q4'22
19%
EBITDA margin Q4'23
vs -21% Q4'22
15%
Other cost Q4'23
vs 22% Q4'22
(% of total revenue)
8
Performance 2H-2023 compared to 1H-2023
1H 2023
8%
EBITDA margin
2H 2023
23%
EBITDA margin
9
Decentralisation drives the margin improvement
Management team driving the overall strategy and direction including support functions
Business Area
Manager
Connected
Imaging
Business Area
Manager
Woman & Child
Business Area
Manager
Medication
Management
Business Area
Manager
LIMS
Business Area
Manager
Health
Analytics
Business Area
Manager
Emergency
Business Area
Manager
Aygo AS
Each Business Area Manager acts as "CEO" in its business area | ||||
Organic Growth | P&L | Capital Discipline | BIB | Consulting profit centre |
Incentivised to deliver on | Incentivised to deliver on | Monitoring R&D capex | Decentralised BIB processes | Development, testing and |
consulting at market prices - | ||||
spend and cash conversion | ||||
organic growth | EBITDA | reduce time-to-finalisation | both internally and | |
per business area | ||||
externally | ||||
10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Omda AS published this content on 29 February 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2024 11:12:46 UTC.